©TheCanadian Journal ofUrology™: International Supplement, April 2014
76
Practical guide to theuseof radium 223dichloride
40.Turner JH, Claringbold PG, Hetherington EL, Sorby P,
Martindale AA. A phase I study of samarium-153
ethylenediaminetetramethylene phosphonate therapy
for disseminated skeletal metastases.
J Clin Oncol
1989;7(12):
1926-1931.
41.Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking
radiopharmaceuticals in the treatmentofmetastaticbonepain.
J CancerResClinOncol
2005;131(1):60-66.
42.Liepe K, Kotzerke J. A comparative study of 188Re-HEDP,
186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of
painful skeletal metastases.
Nucl Med Commun
2007;28(8):
623-630.
43.Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R,
Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of
treatment efficacy of painful bonemetastases in prostate and
breast carcinoma.
NuclMedCommun
2007;28(4):245-250.
44.Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear
energy transfer irradiation targeted to skeletal metastases by
thealpha-emitter223Ra:adjuvantoralternative toconventional
modalities?
ClinCancerRes
2006;12(20Pt 2):6250s-6257s.
45.NilssonS, FranzenL,ParkerCetal.Bone-targeted radium-223
in symptomatic, hormone-refractory prostate cancer:
a randomised, multicentre, placebo-controlledphase II study.
LancetOncol
2007;8(7):587-594.
